$FC

Why Franklin Covey Stock Plummeted Today

Franklin Covey (FC) shares fell 12.9% on Thursday after the company reported Q3 FY2026 results (ended May 31) below Wall Street expectations and issued weaker-than-expected forward guidance. EPS was $0.27 on sales of $67.8M vs estimates of about $0.31 on ~$68.3M revenue; guidance called for $260M–$267M sales vs prior $265M–$275M.

Original reporting
Published Jul 2, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Franklin Covey Stock Plummeted Today — source image
Decision brief

The 30-second read

$FCBearishMed
01

Why it matters

The key new information is a below-consensus earnings/revenue print and a guidance cut for FY sales, which directly explains the double-digit stock decline described for Thursday.

02

Market read

Guidance reduction and earnings miss are likely to drive estimate revisions and continued volatility in FC shares.

03

What to watch

The article doesn’t discuss margin drivers, backlog, or contract timing; traders may be able to reassess once management clarifies what’s behind the guidance reduction.

Relevance 8/10Novelty 8/10Timing: after-hours July 1 results and guidance; selloff into Thursday close

Background

Franklin Covey’s fiscal 2026 third quarter ended May 31; the company released results and forward guidance after the July 1 market close.

Company-level read

Ticker impact

$FCBearishHigh confidence
Context

Franklin Covey reported Q3 FY2026 EPS of $0.27 and revenue of $67.8M, both below consensus, and guided FY sales below prior range.

Expected impact

Bearish bias for the next few sessions as traders reprice FY revenue expectations and margin/earnings trajectory.

Evidence & confidence

The article provides concrete, time-relevant datapoints: below-consensus EPS/revenue and a guidance cut from $265–$275M to $260–$267M.

Market effects

Signals continued pressure on small-cap business-services/consulting demand expectations when guidance is trimmed.

Limited; move is primarily company-specific with broader indices described as flat/only mildly down.

Low; no cross-border deal, regulation, or macro shock tied to FC in the text.

Counterpoint

The revenue growth is modestly positive (~+1% YoY) and EPS improved vs the prior-year quarter, so the selloff may overreact to the guidance midpoint.

Key entities

  • Franklin Covey

    FC reported Q3 FY2026 EPS $0.27 on $67.8M sales and guided FY sales to $260M–$267M, below prior range and consensus.

Related articles

$FCMed

Franklin Covey Co. Q3 2026 Earnings Call Summary

Franklin Covey Co. reported Q3 2026 momentum driven by higher client retention/expansion and North America enterprise growth, including a third straight quarter of rising invoiced amounts. Services booking pace rose 25% YTD. Fiscal 2027 outlook calls for faster revenue growth and operating leverage, but revenue guidance was cut ~$6M due to timing, education budget, and geopolitical impacts; gross margin fell to 73.9% from 76.5%.

$FCMed

FRANKLIN COVEY CO (FC): Results of Operations and Financial Condition

FRANKLIN COVEY CO (FC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 fc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release 13907 S. Minuteman Drive, Suite 500 Draper, UT 84020 www.franklincovey.com FRANKLIN COVEY REPORTS THIRD QUARTER FISCAL 2026 FINANCIAL RESULTS Consolidated Third Quarter Revenue Increases 1% to $67.8 Million Invoic

$NVOHighAI 8/10

Novo Nordisk shares fall by up to 7% in Denmark — CNBC

Novo Nordisk shares dropped 7% in early trading on September 21, 2026, after the company announced new growth targets for its obesity treatment drugs. The firm aims to launch over five potential multi-blockbuster drugs by 2030 and expects sales of over 150 billion Danish kroner ($23 billion) by 2035. Novo Nordisk also anticipates matching industry revenue growth rates from 2026 to 2030.

$TCOMMed

Citi is bullish on these 2 Chinese travel stocks heading into the autumn holidays

Citi reiterated Buy ratings on Tongcheng (THG) and Trip.com (TCOM), citing attractive valuations and upcoming holidays as potential catalysts. Tongcheng reported Q2 2026 revenue of RMB 5.0 billion and net profit of RMB 851 million. Trip.com faces near-term headwinds but is expected to outperform in 2027. Analysts adjusted TCOM's price target to $60, maintaining Buy ratings.